OHSU Center for Specialized Data Analysis as part of the GDAN

    Research project

    Description

    Project Summary Recent advances in therapeutics have improved survival rates for many cancers. However, nearly all metastatic tumors are incurable, and resistance to therapeutic interventions is nearly universal. There are many reasons for our lack of progress-foremost of which is lack of understanding of mechanisms of response and resistance and lack of markers to identify subsets of patients ideally-suited for specific treatments. Our team brings enormous experience in TCGA and other multi-disciplinary coordinated projects, such as BEAT-AML, and the Stand Up to Cancer West Coast Prostate Cancer Dream Team. The Cancer Genome Atlas (TCGA) was successful because multi-disciplinary teams worked together to create new and innovative knowledge about cancer and we intend to ensure that the GDAN is equally successful. In this application, we have assembled a team of proven investigators from four of the different TCGA groups to extend the successes of TCGA to the projects managed by the Center for Cancer Genomics. Our team will continue our outstanding capabilities at analyzing and interpreting cancer genomic data by deploying data analysis pipelines that support the key capabilities of the network. In addition to the our experience in coordinated network studies, we bring experience with clinical trial design and interpretation. Further, the team has deep expertise at building the computational infrastructure necessary for the GDAN to succeed. For example, in the domain of distributed computing we have deploy pipelines for execution at many sites. We also bring novel methods for integrative pathways and analysis. Finally, we bring our experiences with competitive challenges that ensure that we can identify and deploy the most effective methods for genomic data analyses. Using these strengths we will support the GDAN and the Analysis Working Groups (AWGs) that it serves with two principal objectives. The first objective and second objective, per the RFA, are the ?Development of innovative bioinformatics and computational tools and methodologies?, which will allow us to make clinical and biological correlations and to ?Conduct Integrative analysis of data sets generated by GCCs using the bioinformatics tools developed by each GDAC.? We will achieve these objectives in five specific aims, one administrative aim to support the GDAN and four aims, one for each of the areas where we propose a competency.
    StatusActive
    Effective start/end date9/13/168/31/21

    Funding

    • National Institutes of Health: $421,806.00

    Fingerprint

    Neoplasms
    Atlases
    Genome
    Therapeutics
    Computational Biology
    Genomics
    Prostatic Neoplasms
    Survival Rate
    Research Personnel
    Clinical Trials